Antimicrobial resistance with Recce Pharmaceuticals
In this exclusive interview, Drug Target Review's Taylor Mixides interviews James Graham, CEO of Recce Pharmaceuticals, they explore the company's approach to combat the growing global threat of antimicrobial resistance (AMR). Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of…